Novo Nordisk Soars: Hims & Hers' Zava Deal & Wegovy's Teen Appeal

Novo Nordisk A/S rose 2.06% in premarket trading, with the company's stock price increase potentially influenced by the growing demand for its weight-loss drug Wegovy, as indicated by its rising popularity among American teens and the telehealth platform Hims & Hers' recent revenue boost from offering copies of Wegovy. Additionally, the company's focus on developing and marketing pharmaceutical products, particularly for diabetes and obesity treatment, may have contributed to the positive market sentiment.